JP2013501811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501811A5 JP2013501811A5 JP2012524897A JP2012524897A JP2013501811A5 JP 2013501811 A5 JP2013501811 A5 JP 2013501811A5 JP 2012524897 A JP2012524897 A JP 2012524897A JP 2012524897 A JP2012524897 A JP 2012524897A JP 2013501811 A5 JP2013501811 A5 JP 2013501811A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- months
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 206010043554 thrombocytopenia Diseases 0.000 claims 7
- -1 3-chloro-5-{[4- (4-chlorothiophen-2-yl) -5- (4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl Chemical group 0.000 claims 6
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 6
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 229940068196 placebo Drugs 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000010911 splenectomy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- VYNPRPGSCKKCQV-UHFFFAOYSA-N 4-chlorothiophene Chemical compound ClC1=[C]SC=C1 VYNPRPGSCKKCQV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000009390 immune abnormality Effects 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23415309P | 2009-08-14 | 2009-08-14 | |
| US61/234,153 | 2009-08-14 | ||
| US36547910P | 2010-07-19 | 2010-07-19 | |
| US61/365,479 | 2010-07-19 | ||
| PCT/US2010/045433 WO2011019990A1 (en) | 2009-08-14 | 2010-08-13 | Use of e5501 for stimulating platelet production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501811A JP2013501811A (ja) | 2013-01-17 |
| JP2013501811A5 true JP2013501811A5 (enExample) | 2013-08-01 |
Family
ID=42732726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524897A Pending JP2013501811A (ja) | 2009-08-14 | 2010-08-13 | 血小板産生を刺激するためのｅ５５０１の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110166112A1 (enExample) |
| EP (1) | EP2464352A1 (enExample) |
| JP (1) | JP2013501811A (enExample) |
| WO (1) | WO2011019990A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201406373A (zh) * | 2012-06-29 | 2014-02-16 | Shionogi & Co | 含有具有血栓形成素受體促效作用之化合物之醫藥組合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
| IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| KR19990008109A (ko) * | 1995-04-28 | 1999-01-25 | 나가사까 겐지로 | 1,4-이치환 피페리딘 유도체 |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| CA2337755C (en) * | 1998-09-18 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| JPWO2002062775A1 (ja) * | 2001-02-02 | 2004-06-10 | 山之内製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| EP1364949A4 (en) * | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | JNK INHIBITOR |
| US7638536B2 (en) * | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| AU2003243921B2 (en) * | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| US20040235834A1 (en) * | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
| MXPA06000441A (es) * | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
| EP1655291B1 (en) * | 2003-08-12 | 2016-08-03 | Shionogi & Co., Ltd. | Compounds having thrombopoietin receptor agonism |
| EP1971368A4 (en) * | 2005-11-08 | 2009-08-05 | Astellas Pharma Inc | COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA |
| JP2010500361A (ja) * | 2006-08-08 | 2010-01-07 | アカークス，インコーポレーテッド | ヒトの血小板レベルを増加させるための組成物および方法 |
-
2010
- 2010-08-13 JP JP2012524897A patent/JP2013501811A/ja active Pending
- 2010-08-13 EP EP10744818A patent/EP2464352A1/en not_active Withdrawn
- 2010-08-13 US US12/856,003 patent/US20110166112A1/en not_active Abandoned
- 2010-08-13 WO PCT/US2010/045433 patent/WO2011019990A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016074740A5 (enExample) | ||
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| JP2020514412A5 (enExample) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| JP2013515071A5 (enExample) | ||
| TN2016000500A1 (en) | Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| JP2018513188A5 (enExample) | ||
| JP2017510579A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2016503030A5 (enExample) | ||
| JO3659B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية | |
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| JP2013541583A5 (enExample) | ||
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2016534996A5 (enExample) | ||
| WO2011159100A3 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| JP2007119497A5 (enExample) | ||
| RU2019101226A (ru) | Ингибиторы wnt для применения при лечении фиброза | |
| Chitasombat et al. | Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series | |
| JP2012525391A5 (enExample) | ||
| JP2014520874A5 (enExample) |